Bright Study of Bendamustine/Rituximab versus R-CVP or R-CHOP as First-Line Treatment for Advanced Indolent NHL or MCL


Bright Study of Bendamustine/Rituximab versus R-CVP or R-CHOP as First-Line Treatment for Advanced Indolent NHL or MCL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Brad S Kahl, MD (1/17/13)

Flinn IW et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study. Proc ASH 2012;Abstract 902.

Dr Kahl is Skoronski Chair of Lymphoma Research, Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.